CDK4 and neoplasm: Additional studies highlighted an importance of cyclin D1 levels in resistance of cancer cells to PI3Kα inhibitors and revealed a synergistic anti-tumor effect upon combined targeting with CDK4/6 inhibitors [32,36,37].